Cargando…

Retrospective cohort study on treatment modalities and survival time after oesophageal fistula in patients with oesophageal cancer in a regional cancer care centre in China

BACKGROUND: Oesophageal fistula (perforation) is a devastating complication in patients with oesophageal cancer. The optimal treatment remains uncertain. OBJECTIVE: We sought to present real-world evidence on treatment modalities and survival postfistula in patients with oesophageal cancer. DESIGN,...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Wencai, Jiang, Hui, Liu, Yang, Liu, Xiao, Jiang, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106048/
https://www.ncbi.nlm.nih.gov/pubmed/37045573
http://dx.doi.org/10.1136/bmjopen-2022-069703
_version_ 1785026339334520832
author Xu, Wencai
Jiang, Hui
Liu, Yang
Liu, Xiao
Jiang, Yue
author_facet Xu, Wencai
Jiang, Hui
Liu, Yang
Liu, Xiao
Jiang, Yue
author_sort Xu, Wencai
collection PubMed
description BACKGROUND: Oesophageal fistula (perforation) is a devastating complication in patients with oesophageal cancer. The optimal treatment remains uncertain. OBJECTIVE: We sought to present real-world evidence on treatment modalities and survival postfistula in patients with oesophageal cancer. DESIGN, SETTINGS AND MAIN OUTCOMES: This was a retrospective cohort study of patients with oesophageal cancer with oesophageal fistulae diagnosed between June 2010 and June 2020 in a regional cancer care centre in Zhengzhou, China (n=352). The treatment options included surgical resection, oesophageal stent grafting, gastrostomy, nasogastric tube and conservative care. The primary outcome was survival time (months) postfistula. Inverse probability of treatment weighting (IPTW) life regression was used to estimate the differences in survival time accounting for potential confounders. RESULTS: The median survival time was 2.3 months (IQR: 0.7–6.0 months). Survival times were shorter in patients of male sex, T4 stage and oesophagotracheal versus oesophageal-mediastinal fistulae, and longer for any treatment option versus conservative care. The IPTW life regression analyses showed that in patients with oesophagotracheal fistulae, survival times were longer for stent grafting (+0.90 (95% CI 0.60 to 1.19) months) or gastrostomy (+0.81 (95% CI 0.47 to 1.13) months) versus nasogastric tube. In patients with oesophageal-mediastinal fistulae, survival times were shorter for stent grafting versus nasogastric tube (−0.36 (95% CI –0.63 to –0.09) months) and gastric tube (−0.29 (95% CI −0.50 to –0.08) months). Surgical resection was recorded in nine patients with oesophageal-mediastinal fistulae, and it was associated with the longest survival time in these patients. CONCLUSIONS: Stent grafting or gastrostomy may be preferable to nasogastric tube in survival prognosis for patients with oesophageal cancer with oesophagotracheal fistulae. In contrast, stent grafting may be not preferable to nasogastric tube or gastrostomy in survival prognosis for patients with oesophageal-mediastinal fistulae.
format Online
Article
Text
id pubmed-10106048
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-101060482023-04-17 Retrospective cohort study on treatment modalities and survival time after oesophageal fistula in patients with oesophageal cancer in a regional cancer care centre in China Xu, Wencai Jiang, Hui Liu, Yang Liu, Xiao Jiang, Yue BMJ Open Oncology BACKGROUND: Oesophageal fistula (perforation) is a devastating complication in patients with oesophageal cancer. The optimal treatment remains uncertain. OBJECTIVE: We sought to present real-world evidence on treatment modalities and survival postfistula in patients with oesophageal cancer. DESIGN, SETTINGS AND MAIN OUTCOMES: This was a retrospective cohort study of patients with oesophageal cancer with oesophageal fistulae diagnosed between June 2010 and June 2020 in a regional cancer care centre in Zhengzhou, China (n=352). The treatment options included surgical resection, oesophageal stent grafting, gastrostomy, nasogastric tube and conservative care. The primary outcome was survival time (months) postfistula. Inverse probability of treatment weighting (IPTW) life regression was used to estimate the differences in survival time accounting for potential confounders. RESULTS: The median survival time was 2.3 months (IQR: 0.7–6.0 months). Survival times were shorter in patients of male sex, T4 stage and oesophagotracheal versus oesophageal-mediastinal fistulae, and longer for any treatment option versus conservative care. The IPTW life regression analyses showed that in patients with oesophagotracheal fistulae, survival times were longer for stent grafting (+0.90 (95% CI 0.60 to 1.19) months) or gastrostomy (+0.81 (95% CI 0.47 to 1.13) months) versus nasogastric tube. In patients with oesophageal-mediastinal fistulae, survival times were shorter for stent grafting versus nasogastric tube (−0.36 (95% CI –0.63 to –0.09) months) and gastric tube (−0.29 (95% CI −0.50 to –0.08) months). Surgical resection was recorded in nine patients with oesophageal-mediastinal fistulae, and it was associated with the longest survival time in these patients. CONCLUSIONS: Stent grafting or gastrostomy may be preferable to nasogastric tube in survival prognosis for patients with oesophageal cancer with oesophagotracheal fistulae. In contrast, stent grafting may be not preferable to nasogastric tube or gastrostomy in survival prognosis for patients with oesophageal-mediastinal fistulae. BMJ Publishing Group 2023-04-11 /pmc/articles/PMC10106048/ /pubmed/37045573 http://dx.doi.org/10.1136/bmjopen-2022-069703 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Oncology
Xu, Wencai
Jiang, Hui
Liu, Yang
Liu, Xiao
Jiang, Yue
Retrospective cohort study on treatment modalities and survival time after oesophageal fistula in patients with oesophageal cancer in a regional cancer care centre in China
title Retrospective cohort study on treatment modalities and survival time after oesophageal fistula in patients with oesophageal cancer in a regional cancer care centre in China
title_full Retrospective cohort study on treatment modalities and survival time after oesophageal fistula in patients with oesophageal cancer in a regional cancer care centre in China
title_fullStr Retrospective cohort study on treatment modalities and survival time after oesophageal fistula in patients with oesophageal cancer in a regional cancer care centre in China
title_full_unstemmed Retrospective cohort study on treatment modalities and survival time after oesophageal fistula in patients with oesophageal cancer in a regional cancer care centre in China
title_short Retrospective cohort study on treatment modalities and survival time after oesophageal fistula in patients with oesophageal cancer in a regional cancer care centre in China
title_sort retrospective cohort study on treatment modalities and survival time after oesophageal fistula in patients with oesophageal cancer in a regional cancer care centre in china
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106048/
https://www.ncbi.nlm.nih.gov/pubmed/37045573
http://dx.doi.org/10.1136/bmjopen-2022-069703
work_keys_str_mv AT xuwencai retrospectivecohortstudyontreatmentmodalitiesandsurvivaltimeafteroesophagealfistulainpatientswithoesophagealcancerinaregionalcancercarecentreinchina
AT jianghui retrospectivecohortstudyontreatmentmodalitiesandsurvivaltimeafteroesophagealfistulainpatientswithoesophagealcancerinaregionalcancercarecentreinchina
AT liuyang retrospectivecohortstudyontreatmentmodalitiesandsurvivaltimeafteroesophagealfistulainpatientswithoesophagealcancerinaregionalcancercarecentreinchina
AT liuxiao retrospectivecohortstudyontreatmentmodalitiesandsurvivaltimeafteroesophagealfistulainpatientswithoesophagealcancerinaregionalcancercarecentreinchina
AT jiangyue retrospectivecohortstudyontreatmentmodalitiesandsurvivaltimeafteroesophagealfistulainpatientswithoesophagealcancerinaregionalcancercarecentreinchina